Preoperative serum α-fetoprotein and prognosis after hepatectomy for hepatocellular carcinoma

British Journal of Surgery

Volumn 103, Issue 6, 2016, Pages 716-724

  Yang, S L ^a   Liu, L P ^c   Yang, S ^a   Liu, L ^a   Ren, J W ^a,b   Fang, X ^d   Chen, G G ^a,b   Lai, P B S ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c SHENZHEN PEOPLE'S HOSPITAL   (China)

^d UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; TUMOR MARKER;

ADULT; AGED; BLOOD; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMAN; KAPLAN MEIER METHOD; LIVER NEOPLASMS; LIVER RESECTION; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PREOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RECEIVER OPERATING CHARACTERISTIC; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; ALPHA-FETOPROTEINS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATECTOMY; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 84962622876     PISSN: 00071323     EISSN: 13652168     Source Type: Journal    
DOI: 10.1002/bjs.10093     Document Type: Article

References (29)

1. Altekruse SF, McGlynn KA, Dickie LA, Kleiner DE,. Hepatocellular carcinoma confirmation, treatment, and survival in surveillance, epidemiology, and end results registries, 1992-2008. Hepatology 2012; 55: 476-482.
2. Parpart S, Roessler S, Dong F, Rao V, Takai A, Ji J, et al. Modulation of miR-29 expression by alpha-fetoprotein is linked to the hepatocellular carcinoma epigenome. Hepatology 2014; 60: 872-883.
3. Arrieta O, Cacho B, Morales-Espinosa D, Ruelas-Villavicencio A, Flores-Estrada D, Hernández-Pedro N,. The progressive elevation of alpha fetoprotein for the diagnosis of hepatocellular carcinoma in patients with liver cirrhosis. BMC Cancer 2007; 7: 28.
4. Bruix J, Sherman M, Llovet JM, Beaugrand M, Lencioni R, Burroughs AK et al.; EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001; 35: 421-430.
5. Semenkova LN, Dudich EI, Dudich IV,. Induction of apoptosis in human hepatoma cells by alpha-fetoprotein. Tumour Biol 1997; 18: 261-273.
6. Mitsuhashi N, Kobayashi S, Doki T, Kimura F, Shimizu H, Yoshidome H, et al. Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma. J Gastroenterol Hepatol 2008; 23: e189-e197.
7. Zhang L, He T, Cui H, Wang Y, Huang C, Han F,. Effects of AFP gene silencing on apoptosis and proliferation of a hepatocellular carcinoma cell line. Discov Med 2012; 14: 115-124.
8. Witjes CD, Polak WG, Verhoef C, Eskens FA, Dwarkasing RS, Verheij J, et al. Increased alpha-fetoprotein serum level is predictive for survival and recurrence of hepatocellular carcinoma in non-cirrhotic livers. Dig Surg 2012; 29: 522-528.
9. Kudo A, Matsumura S, Ban D, Irie T, Ochiai T, Tanaka S, et al. Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function? Hepatol Res 2014; 44: E437-E446.
10. Gómez-Rodríguez R, Romero-Gutiérrez M, Artaza-Varasa T, González-Frutos C, Ciampi-Dopazo JJ, de-la-Cruz-Pérez G et al. The value of the Barcelona Clinic Liver Cancer and alpha-fetoprotein in the prognosis of hepatocellular carcinoma. Rev Esp Enferm Dig 2012; 104: 298-304.
11. Giannini EG, Marenco S, Borgonovo G, Savarino V, Farinati F, Del Poggio P, et al.; Italian Liver Cancer Group. Alpha-fetoprotein has no prognostic role in small hepatocellular carcinoma identified during surveillance in compensated cirrhosis. Hepatology 2012; 56: 1371-1379.
12. Shim JH, Yoon DL, Han S, Lee YJ, Lee SG, Kim KM, et al. Is serum alpha-fetoprotein useful for predicting recurrence and mortality specific to hepatocellular carcinoma after hepatectomy? A test based on propensity scores and competing risks analysis. Ann Surg Oncol 2012; 19: 3687-3696.
13. Toyoda H, Kumada T, Kaneoka Y, Osaki Y, Kimura T, Arimoto A, et al. Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC. J Hepatol 2008; 49: 223-232.
14. Giannini EG, Sammito G, Farinati F, Ciccarese F, Pecorelli A, Rapaccini GL et al.; Italian Liver Cancer Group. Determinants of alpha-fetoprotein levels in patients with hepatocellular carcinoma: implications for its clinical use. Cancer 2014; 120: 2150-2157.
15. Ma WJ, Wang HY, Teng LS,. Correlation analysis of preoperative serum alpha-fetoprotein (AFP) level and prognosis of hepatocellular carcinoma (HCC) after hepatectomy. World J Surg Oncol 2013; 11: 212.
16. Zhang Q, Shang L, Zang Y, Chen X, Zhang L, Wang Y, et al. Alpha-fetoprotein is a potential survival predictor in hepatocellular carcinoma patients with hepatitis B selected for liver transplantation. Eur J Gastroenterol Hepatol 2014; 26: 544-552.
17. Zhou L, Rui JA, Wang SB, Chen SG, Qu Q,. The significance of serum AFP cut-off values, 20 and 400 ng/ml in curatively resected patients with hepatocellular carcinoma and cirrhosis might be of difference. Hepatogastroenterology 2012; 59: 840-843.
18. Altman DG, McShane LM, Sauerbrei W, Taube SE,. Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK): explanation and elaboration. PLoS Med 2012; 9: e1001216.
19. Collins GS, Reitsma JB, Altman DG, Moons KG,. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): the TRIPOD Statement. Br J Surg 2015; 102: 148-158.
20. Chan SL, Mo F, Johnson PJ, Siu DY, Chan MH, Lau WY, et al. Performance of serum alpha-fetoprotein levels in the diagnosis of hepatocellular carcinoma in patients with a hepatic mass. HPB (Oxford) 2014; 16: 366-372.
21. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-474.
22. Tibshirani R., The lasso method for variable selection in the Cox model. Stat Med 1997; 16: 385-395.
23. Zou KH, O'Malley AJ, Mauri L,. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. Circulation 2007; 115: 654-657.
24. Cheung YS, Chan HL, Wong J, Lee KF, Poon TC, Wong N, et al,. Elevated perioperative transaminase level predicts intrahepatic recurrence in hepatitis B-related hepatocellular carcinoma after curative hepatectomy. Asian J Surg 2008; 31: 41-49.
25. Chong CC, Lee KF, Ip PC, Wong JS, Cheung SY, Wong J, et al. Pre-operative predictors of post-hepatectomy recurrence of hepatocellular carcinoma: can we predict earlier? Surgeon 2012; 10: 260-266.
26. Johnson PJ,. The role of serum alpha-fetoprotein estimation in the diagnosis and management of hepatocellular carcinoma. Clin Liver Dis 2001; 5: 145-159.
27. Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol 2009; 16: 1832-1842.
28. Huo TI, Huang YH, Lui WY, Wu JC, Lee PC, Chang FY, et al. Selective prognostic impact of serum alpha-fetoprotein level in patients with hepatocellular carcinoma: analysis of 543 patients in a single center. Oncol Rep 2004; 11: 543-550.
29. Tangkijvanich P, Anukulkarnkusol N, Suwangool P, Lertmaharit S, Hanvivatvong O, Kullavanijaya P, et al. Clinical characteristics and prognosis of hepatocellular carcinoma: analysis based on serum alpha-fetoprotein levels. J Clin Gastroenterol 2000; 31: 302-308.